Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Abeona Therapeutics

Applied Therapeutics Inc

Ennis

Proteostasis Therapeutics

The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

US Dollar Flexes Muscles Against Other Currencies: 5 Winners

NEWTOWN, Pa., Jan.  23, 2020  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has regained the rights to rigosertib in Greater China.  Onconova regained the rights from HanX Biopharmaceuticals (HanX) as a result of the termination of the Onconova-HanX License Agreement pursuant to its terms due to HanX failing to make required payments under the agreement.  In exchange for transition assistance and upon further regulatory, development and commercial progress in Greater China, HanX may be eligible to receive from Onconova incentive milestones and royalty payments.  The Greater China territory, including mainland China, Hong Kong, Macau and Taiwan, represents one of the key world pharmaceutical markets. 

Onconova Therapeutics Regains Rigosertib Rights in Greater China

NEWTOWN, Pa., Jan.  03, 2020  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the closing of its previously announced registered direct offering of 27,662,518 shares of its common stock at a purchase price of $0.3615 per share, for aggregate gross proceeds of approximately $10 million in a registered direct offering priced at-the-market under Nasdaq rules.

Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market

NEWTOWN, Pa., Dec.  31, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has entered into definitive agreements with [two] healthcare-focused institutional investors for the issuance and sale in a registered direct offering of 27,662,518 shares of its common stock at a purchase price of $0.3615 per share, for aggregate gross proceeds of approximately $10 million in a registered direct offering priced at-the-market under Nasdaq rules.

Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market

NEWTOWN, Pa., Dec.  19, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the closing of its previously announced registered direct offering of 13,878,864  shares of its common stock and warrants to purchase up to 6,939,432 shares of its common stock, at a combined purchase price of $0.36026 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million. The registered direct offering priced at-the-market under Nasdaq rules.

Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market

NEWTOWN, Pa., Dec.  18, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has entered into definitive agreements with two healthcare focused institutional investors for the issuance and sale in a registered direct offering of 13,878,864 shares of its common stock and warrants to purchase up to 6,939,432 shares of its common stock, at a combined purchase price of $0.36026 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million in a registered direct offering priced at-the-market under Nasdaq rules.

Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market

NEWTOWN, Pa., Dec.  17, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), and Pint Pharma, a European-based pharmaceutical company focused on the development, registration and commercialization of specialty-based treatments for the Latin American market, today announced the receipt of approval from the Brazilian Health authority to initiate the INSPIRE Trial in Brazil with intravenous rigosertib in Higher-Risk MDS (HR-MDS).  In November 2019 enrollment in the INSPIRE Trial surpassed 90% percent of the required enrollment, and the Company continues to anticipate reporting topline data in the first half of 2020, following full enrollment and reaching the number of required survival events.

Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil

NEWTOWN, Pa., Dec.  10, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the closing of its previously announced registered direct offering of 14,326,648 shares of its common stock and warrants to purchase up to 7,163,324 shares of its common stock, at a combined purchase price of $0.349 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million. The registered direct offering priced at-the-market under Nasdaq rules.

Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market.

NEWTOWN, Pa., Dec.  09, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced data presented from INSPIRE related abstracts at the American Society of Hematology (ASH) 2019 Annual Meeting.  Preliminary genomics data from the INSPIRE Trial was presented.  In addition, updated data from the Phase 2 Trial of Oral Rigosertib + Azacitidine (AZA) Versus Single Agent AZA in Treatment-Naive Patients with HR-MDS was presented in an oral presentation.  The Company believes these abstracts represent important progress for the development programs of intravenous (IV) and oral rigosertib.

Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical T

NEWTOWN, Pa., Dec.  09, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has entered into definitive agreements with healthcare focused institutional investors for the issuance and sale in a registered direct offering of 14,326,648 shares of its common stock and warrants to purchase up to 7,163,324 shares of its common stock, at a combined purchase price of $0.349 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million in a registered direct offering priced at-the-market under Nasdaq rules.

Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market.

NEWTOWN, Pa. and LUXEMBOURG, Dec.  06, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), and Inceptua Medicines Access (a business unit of the Inceptua Group), a global pharmaceutical company and service partner, today announced that they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.

Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

Offering led by healthcare dedicated funds, including Knight Therapeutics Inc.,  along with  officers and directors of Onconova Offering led by healthcare dedicated funds, including Knight Therapeutics Inc.,  along with  officers and directors of Onconova

Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering

NEWTOWN, Pa., Nov.  21, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced that it has priced a public offering of an aggregate of 55,000,000 shares of Onconova’s common stock (or common stock equivalents), together with accompanying common stock warrants, at a public offering price of $0.20 per share and associated warrant. Each share of common stock (or common stock equivalent) was sold in the offering together with a common warrant to purchase one share of common stock at an exercise price of $0.20 per share. The common stock warrants are exercisable immediately and will expire five years from the date of issuance.  The offering was led by healthcare dedicated funds and included officers and directors of Onconova. 

Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering

NEWTOWN, Pa., Nov.  21, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced they have entered into a Distribution, License and Supply Agreement with Knight Therapeutics Inc. (“Knight”), a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, whereby Knight shall have the exclusive rights to commercialize rigosertib in Canada. In addition, Onconova may be entitled to receive clinical, regulatory and sales-based milestone payments up to CAD 33.95 million and tiered double-digit royalties on net sales.

Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada

NEWTOWN, Pa., Sept.  23, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to purchase an aggregate of 2,136,193 shares of its common stock, at a purchase price of $1.60 per share in a registered direct offering for aggregate gross proceeds of approximately $3.4 million.  The offering is expected to close on or about September 25, 2019, subject to the satisfaction of customary closing conditions.

Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock

NEWTOWN, Pa., Sept.  18, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS) today announced that it has decided to terminate the public offering of shares of its common stock with the current bank previously announced in a preliminary prospectus supplement filed and supplemented September 13, 2019 and September 17, 2019 respectively. The decision to terminate results from an assessment by the Company that current equity market conditions are not conducive for an offering on terms that would be in the best interests of the Company's shareholders.

Onconova Therapeutics Announces Termination of Proposed Public Offering

NEWTOWN, Pa., Sept.  16, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), will present at the RAS-Targeted Drug Discovery Summit being held September 17-19 in Boston, Massachusetts.  Dr. Steven Fruchtman, President & CEO, will be presenting.  Also attending the conference will be Avi Oler, VP Corporate Development.

Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q2 2019 Results - Earnings Call Transcript

Onconova (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q1 2019 Results - Earnings Call Transcript

Onconova Therapeutics (ONTX) CEO, Steve Fruchtman on Q4 2018 Results - Earnings Call Transcript

News for Onconova Therapeutics Stock (ONTX)